Researchers wanted to determine whether eating high doses of peanut products beginning in infancy would have any adverse effects on infant and child growth and nutrition.
"The new results provide reassurance that early-life peanut consumption has no negative effect on children's growth and nutrition," said Anthony S Fauci from National Institute of Allergy and Infectious Diseases (NIAID) in the US.
The results of a previous Learning Early About Peanut Allergy (LEAP) trial showed that introducing peanut products into the diets of infants deemed at high risk for peanut allergy led to an 81 per cent relative reduction in subsequent development of the allergy compared to avoiding peanut altogether.
These regimens were continued until the children were 5 years old. Researchers monitored the children at recurring health care visits, and asked their parents and caregivers to complete dietary questionnaires and food diaries.
In the current study, researchers compared the growth, nutrition and diets of the LEAP peanut consumers and avoiders. Many of the participants were breastfeeding at the beginning of LEAP.
Researchers did not observe differences in height, weight or body mass index - a measure of healthy weight status - between the peanut consumers and avoiders at any point during the study.
This was true even when researchers compared the subgroup of children who consumed the greatest amount of peanut protein with those who avoided peanut entirely.
They made some different food choices than the avoiders, researchers noted. For example, consumers ate fewer chips and savoury snacks.
Both groups had similar total energy intakes from food and comparable protein intakes, although the peanut consumers had higher fat intakes and avoiders had higher carbohydrate intakes.
"Overall, these findings indicate that early-life introduction of peanut-containing foods as a strategy to prevent the subsequent development of peanut allergy is both feasible and nutritionally safe, even at high levels of peanut consumption," said Marshall Plaut from NIAID.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
